Atara Biotherapeutics, Inc. 8-K

What Happened

• On May 7, 2026, Atara Biotherapeutics, Inc. filed an 8‑K and issued a press release titled “Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel.”
• The release follows a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the Complete Response Letter (CRL) issued for the EBVALLO™ Biologics License Application (BLA) on January 9, 2026.
• The press release is attached to the 8‑K as Exhibit 99.1. The filing was signed by AnhCo Thieu Nguyen, Ph.D., President and Chief Executive Officer, on behalf of the company.

Key Details

• Filing date: May 7, 2026 (Form 8‑K, Item 8.01 – Other Events).
• Regulatory context: Type A meeting with FDA regarding the CRL for the EBVALLO™ BLA issued January 9, 2026.
• Exhibit: Press release provided as Exhibit 99.1 and incorporated by reference in the filing.
• Signature: 8‑K signed by CEO AnhCo Thieu Nguyen, Ph.D.

Why It Matters

• This filing signals continued regulatory engagement between Atara and the FDA on tabelecleucel (EBVALLO™ BLA). Outcomes from the Type A meeting and details in the press release could affect the company’s regulatory timeline and plans for potential approval or next steps.
• Investors should review the attached press release (Exhibit 99.1) for specifics on FDA feedback, any required actions by Atara, and updated timelines or milestones that could influence the company’s development outlook.